考比替尼

Cobimetinib

Abstract

No information is available on the clinical use of cobimetinib during breastfeeding. Because cobimetinib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 44 hours, and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during cobimetinib therapy and for 2 weeks after the last dose.

摘要

关于考比替尼在母乳喂养期间的临床应用尚无可用信息。由于考比替尼与血浆蛋白的结合率为90%，其在乳汁中的含量可能较低。然而，其半衰期约为44小时，可能会在婴儿体内蓄积。制造商建议在考比替尼治疗期间及最后一剂后2周内停止母乳喂养。